Salarius Pharmaceuticals Adds Fox Chase Cancer Center to Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Press/Media

Period	Jul 13 2021

Media coverage

Title	Salarius Pharmaceuticals Adds Fox Chase Cancer Center to Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas
Media name/outlet	Morningstar.com
Country/Territory	United States
Date	07/13/21
URL	https://www.morningstar.com/news/globe-newswire/8279118/salarius-pharmaceuticals-adds-fox-chase-cancer-center-to-ongoing-trial-of-seclidemstat-as-a-treatment-for-ewing-sarcoma-and-fet-rearranged-sarcomas
Persons	Johnathan R. Whetstine, Margaret von Mehren